<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826618</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4148s</org_study_id>
    <nct_id>NCT00826618</nct_id>
  </id_info>
  <brief_title>Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema</brief_title>
  <official_title>Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Uveitic Cystoid Macular Edema (CME) is a major cause of visual loss associated with uveitis.
      Systemic and/or local corticosteroid therapy and systemic immunosuppression with
      steroid-sparing agents such as cyclosporine, methotrexate, azathioprine, or others,
      effectively treats uveitis and associated CME in many patients. However, in many cases, CME
      persists in spite of adequate suppression of uveitis. No consensus exists on how best to
      treat such cases. The further addition of immunosuppressive agents appears to have little
      effect on this form of CME. Oral corticosteroids are useful, but high dosage and prolonged
      use can be associated with serious side-effects. Periocular and intravitreal corticosteroid
      injections are associated with well-known, significant side effects such as glaucoma and
      cataract formation.

      Vascular endothelial growth factor (VEGF) is suspected to play a role in the loss of vascular
      integrity in the eye and known to be induced by inflammatory cytokines, such as interleukin
      interleukin (IL)-1Î² and IL-6, which are elevated intraocularly in uveitis. In addition, it
      has been demonstrated that aqueous VEGF concentrations are statistically significantly higher
      in those uveitis patients with CME than those without CME. Inhibition of inappropriate VEGF
      activity is a potential approach to treatment of CME in uveitis given our current knowledge
      of the pathophysiology of this condition and also because of the clinical need for additional
      treatment options for these patients. Ranibizumab, a recombinant, humanized monoclonal
      antibody antigen-binding fragment (Fab) that neutralizes all active forms of VEGF-A, would
      target this pathway and may be useful in cases of persistent CME in uveitis patients.

      The objective of this study is to determine if an anti-VEGF agent, Lucentis, is safe and
      effective in leading to regression of macular edema due to chronic non-infectious uveitis in
      patients with well-controlled uveitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months.</measure>
    <time_frame>1 year</time_frame>
    <description>Mean change in best corrected visual acuity (assessed by the ETDRS chart at 4 m) from baseline at 12 months following first intravitreal injection of ranibizumab was 12.2 ETDRS letters (P = 0.015).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Mean Change in Best Corrected Visual Acuity (BCVA) (Assessed by the ETDRS Chart at 4 Meters) From Baseline at 12 Months Will be Computed With a T-test.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients With 15 Letters (3 Lines) of Visual Acuity Improvement at 30, 60, 90, 120 Days, and 12 Months.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Mean Change in Foveal Retinal Thickness From Baseline at 7 Days, and at 30, 60, 90, 120 Days, and 12 Months Will be Computed Using a T-test.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Ocular and Non-ocular Adverse Events Will be Evaluated Through Month 24.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Uveitic Cystoid Macular Edema</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab</intervention_name>
    <description>This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be eligible if the following criteria are met:

          1. Ability to provide written informed consent and comply with study assessments for the
             full duration of the study.

          2. Age &gt; 18 years

          3. Non-infectious uveitis in study eye.

          4. Stable anti-uveitis medical regimen for at least one month prior to injection and
             controlled uveitis in the judgment of the investigator.

          5. Vision 20/40 or worse in study eye.

          6. Cystoid Macular Edema (CME) on fluorescein angiography (FA)

          7. Optical Coherence Tomography (OCT) demonstrating thickness greater than 300 microns in
             the central subfield.

          8. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT
             testing and retinal photography.

        Only one eye will be assessed in the study. If both eyes are eligible, the investigator
        will determine which eye will be entered into the study.

        Exclusion Criteria:

          1. Previous intravitreal triamcinolone injection in study eye within 3 months of study
             injection.

          2. Use of more than two glaucoma medicines for study eye.

          3. Significant epiretinal membrane as judged by treating physician.

          4. Evidence of vitreomacular traction on OCT.

          5. Previous vitrectomy in study eye.

          6. Pregnancy (positive pregnancy test) or lactation.

          7. Premenopausal women not using adequate contraception. The following are considered
             effective means of contraception: surgical sterilization or use of oral
             contraceptives, barrier contraception with either a condom or diaphragm in conjunction
             with spermicidal gel, an intrauterine device (IUD), or contraceptive hormone implant
             or patch.

          8. Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated.

          9. Participation in another simultaneous IND trial.

         10. Treatment for CME with intravitreal Lucentis, Macugen, or Avastin within 6 weeks prior
             to enrollment in this study.

         11. Uncontrolled inflammation in the study eye.

         12. Current vitreous hemorrhage.

         13. Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either
             eye.

         14. Known allergy to any component of the study drug.

         15. Intraocular pressure &gt; 25 mm Hg despite treatment with glaucoma medications.

         16. Blood pressure &gt; 180/110 (systolic above 180 OR diastolic above 110). If blood
             pressure is brought below 180/110 by anti-hypertensive treatment, the subject can
             become eligible.

         17. Major non-ocular surgery planned during the next 6 months.

         18. Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated.

         19. No Avastin use permitted in fellow eye during study.

         20. Unwilling or unable to follow or comply with all study related procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas A Albini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bascom Palmer Eye Insitute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer of the Palm Beaches</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <results_first_submitted>August 6, 2014</results_first_submitted>
  <results_first_submitted_qc>August 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2014</results_first_posted>
  <last_update_submitted>August 24, 2014</last_update_submitted>
  <last_update_submitted_qc>August 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Thomas Albini</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>Cystoid Macular Edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab</title>
          <description>ranibizumab: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab</title>
          <description>ranibizumab: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months.</title>
        <description>Mean change in best corrected visual acuity (assessed by the ETDRS chart at 4 m) from baseline at 12 months following first intravitreal injection of ranibizumab was 12.2 ETDRS letters (P = 0.015).</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab</title>
            <description>ranibizumab: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME. Mean change in BCVA (assessed by the ETDRS chart at 4 m) from baseline at 12 months was 12.2 ETDRS letters (P = 0.015).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months.</title>
          <description>Mean change in best corrected visual acuity (assessed by the ETDRS chart at 4 m) from baseline at 12 months following first intravitreal injection of ranibizumab was 12.2 ETDRS letters (P = 0.015).</description>
          <units>Change in ETDRS Letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Compare final visual acuity to baseline visual acuity</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0015</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change in Best Corrected Visual Acuity (BCVA) (Assessed by the ETDRS Chart at 4 Meters) From Baseline at 12 Months Will be Computed With a T-test.</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients With 15 Letters (3 Lines) of Visual Acuity Improvement at 30, 60, 90, 120 Days, and 12 Months.</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Mean Change in Foveal Retinal Thickness From Baseline at 7 Days, and at 30, 60, 90, 120 Days, and 12 Months Will be Computed Using a T-test.</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Ocular and Non-ocular Adverse Events Will be Evaluated Through Month 24.</title>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab</title>
          <description>ranibizumab: This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Uveitis in fellow eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Anterior uveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Ocular pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The main limitation of this study is the small number of patients.There is no comparative arm to better define the relative efficacy of ranibizumab as compared with intraocular steroids or other treatments.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas A. Albini, MD</name_or_title>
      <organization>University of Miami</organization>
      <phone>3054825006</phone>
      <email>talbini@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

